Online inquiry

IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10429MR)

This product GTTS-WQ10429MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MSTN gene. The antibody can be applied in Cachexia research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005259.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2660
UniProt ID O14793
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10429MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11573MR IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MG-A271
GTTS-WQ13025MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ8788MR IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IBI-306
GTTS-WQ15416MR IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA TSR-022
GTTS-WQ7134MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA FE 999302
GTTS-WQ11624MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MGD-006
GTTS-WQ9868MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA K7153A
GTTS-WQ11948MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MLTA3698A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW